Does Humana Cover Prolia?

How Humana Structures Prolia Coverage

Humana covers Prolia, but the benefit category that pays for it varies by plan type. This distinction matters enormously for your out-of-pocket cost.

Prolia is a biologic injectable administered by a clinician every six months. Because a nurse or physician gives the injection in-office, Medicare classifies it as a Part B drug, not a Part D drug. Humana's Medicare Advantage plans mirror this logic.

Medicare Advantage (Part C) Plans

On Humana's Medicare Advantage plans, Prolia typically falls under the medical benefit rather than the pharmacy benefit. Your physician bills Medicare Part B using HCPCS code J0897. Humana then pays its share, and you owe 20% of the Medicare-approved amount after your Part B deductible ($240 in 2024).

The Medicare-allowed amount for one Prolia injection is roughly $900 to $1,100 depending on the care setting, putting your 20% share at $180 to $220 per injection before any supplemental coverage applies. Some Humana Gold Plus HMO or PPO plans reduce this further with lower specialty cost-sharing tiers.

Part D Prescription Plans

If you have a standalone Humana Part D plan (not a Medicare Advantage plan), Prolia almost never appears on the formulary. Part D does not cover physician-administered biologics by design. The Centers for Medicare and Medicaid Services [CMS] guidance clarifies that drugs "incident to a physician's service" are Part B drugs [1]. Asking your Part D plan to cover Prolia will result in a denial that is not worth appealing on formulary grounds.

Commercial (Employer and Individual) Plans

Humana commercial plans place Prolia on Tier 4 or Tier 5 of the specialty drug formulary in most cases. Cost-sharing ranges from 20% to 33% coinsurance after the deductible. Annual out-of-pocket maximums cap your exposure, but the 2024 ACA limit for individual plans is $9,450, meaning a year of Prolia could consume a large portion of that cap if deductibles are high.

What Conditions Qualify You for Prolia Coverage

The FDA approved Prolia for four distinct indications, and Humana's coverage criteria track FDA labeling closely [2].

Postmenopausal Osteoporosis

This is the most common covered indication. Humana requires documentation of a bone mineral density (BMD) T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck, measured by dual-energy X-ray absorptiometry (DXA). Alternatively, a T-score between -1.0 and -2.5 combined with a prior fragility fracture or a 10-year FRAX major osteoporotic fracture probability at or above 20% also satisfies most Humana clinical criteria.

The FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every six months reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months versus placebo [3]. Humana's medical policy documents cite fracture risk reduction as the primary clinical justification for coverage.

Male Osteoporosis

The FDA approved Prolia for men with osteoporosis at high fracture risk in 2012 [2]. Humana covers this indication with identical T-score documentation requirements to those used for postmenopausal women.

Glucocorticoid-Induced Osteoporosis

Patients on systemic corticosteroids (prednisone equivalent at or above 7.5 mg daily for at least six months) qualify for Prolia coverage on most Humana plans, provided BMD criteria are met [4]. The American College of Rheumatology 2022 guidelines strongly recommend anabolic or antiresorptive therapy for high-risk patients on long-term glucocorticoids [4].

Bone Loss from Cancer Therapy

Prolia 60 mg every six months is approved for women receiving aromatase inhibitor therapy for breast cancer and for men on androgen deprivation therapy for nonmetastatic prostate cancer. Humana covers both oncology-adjacent indications, though oncology-specific prior authorization criteria may apply separately from the standard osteoporosis pathway.

Prior Authorization Requirements for Prolia on Humana Plans

Prior authorization (PA) is required for Prolia on nearly every Humana plan type. Failing to obtain PA before the injection is the single most common reason members receive an unexpected bill.

What the PA Packet Must Include

Humana's standard Prolia PA criteria require all of the following:

• A DXA scan result (T-score) from within the past 24 months, performed at an approved imaging center
• The prescribing physician's ICD-10 diagnosis code (M81.0 for postmenopausal osteoporosis without fracture, M80 series for osteoporosis with fracture)
• Documentation that the patient either tried and failed bisphosphonate therapy (alendronate, risedronate, or zoledronic acid) or has a clinical contraindication to bisphosphonates, such as severe renal impairment with eGFR <35 mL/min/1.73m², esophageal abnormalities, or documented intolerance
• Calculation or documentation of FRAX 10-year fracture probability if T-score is between -1.0 and -2.5
• Prescribing physician's NPI number and office contact information for peer-to-peer review if needed

Bisphosphonate Step Therapy

Most Humana plans apply step therapy, meaning bisphosphonates must be tried first. Generic alendronate (Fosamax) costs under $15 per month on most Part D plans, making it the default first-line agent per the American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines [5]. Prolia is reserved for patients at very high fracture risk or those who cannot tolerate or absorb oral bisphosphonates.

PA Turnaround Times

Standard PA decisions must be issued within 14 calendar days of a complete submission under CMS rules for Medicare Advantage plans [6]. Urgent PA requests (when delay would seriously jeopardize health) must receive a decision within 72 hours. Ask your physician's office to flag the request as urgent if the injection appointment is within one week.

How to Check Your Specific Humana Plan's Coverage

Coverage details differ plan-to-plan even within Humana's product lines. Four steps confirm your exact benefits before you receive the injection.

1. Call the member services number on the back of your Humana ID card and ask specifically whether HCPCS J0897 (denosumab 60 mg) requires prior authorization on your plan.
2. Request a Summary of Benefits and Coverage (SBC) document and look for "specialty biologics" or "self-administered vs. Physician-administered drugs" in the benefits summary.
3. Ask your prescribing physician's billing coordinator to run an eligibility and benefits check through Humana's provider portal before scheduling the injection.
4. If you have Medicare Advantage, verify the plan's Part B drug cost-sharing tier for J0897 specifically, since some plans place Part B drugs on a preferred or non-preferred specialty tier with different copay amounts.

What Happens If Humana Denies Coverage

A denial is not the end. The appeals process has multiple levels, and denials are frequently reversed.

Level 1 Appeal

Submit a written appeal within 60 days of the denial notice for Medicare Advantage plans. Include the original PA documentation, a letter of medical necessity from your physician, and the relevant clinical trial data. The FREEDOM trial data showing 68% vertebral fracture risk reduction [3] is directly relevant to medical necessity arguments.

Humana must respond to a standard Level 1 appeal within 60 calendar days for Part D cases and 60 days for medical benefit cases [6]. Expedited appeals receive a 72-hour response window.

Peer-to-Peer Review

Before filing a formal appeal, your physician can request a peer-to-peer call with Humana's medical director. Published research indicates that peer-to-peer reviews reverse 30% to 50% of specialty drug denials [7]. This call costs nothing and adds zero time to the appeals clock.

Independent Review Organization (IRO)

If Humana upholds the denial at Level 1, you can escalate to an IRO for Medicare Advantage cases. IRO reviewers are independent of Humana. CMS data show IROs overturn Medicare Advantage plan denials at a meaningful rate, particularly for drugs with strong guideline support [8].

External Appeal for Commercial Plans

Commercial plan members in most states have the right to external appeal through the state insurance commissioner's office. The Affordable Care Act mandates external review rights for most employer-sponsored and individual market plans [9].

Prolia Cost Without Insurance or With a Coverage Gap

If coverage is denied or you are in a coverage gap, two cost-reduction pathways exist.

Amgen's Prolia SupportPlus Program

Amgen, Prolia's manufacturer, operates the Prolia SupportPlus program. Eligible patients with commercial insurance and household income at or below 500% of the federal poverty level may qualify for free drug. Uninsured patients may also qualify. The program covers the cost of the drug itself but not the administration fee charged by the physician's office. Call 1-800-772-6436 or visit Amgen's website to apply.

Medicare Inflation Reduction Act Drug Price Negotiation

The Inflation Reduction Act of 2022 authorized CMS to negotiate prices for high-expenditure Part B and Part D drugs. Denosumab has been named as a candidate for future negotiation cycles given its high total Medicare spend. If negotiated, the maximum out-of-pocket cap for negotiated Part D drugs ($2,000 annually starting in 2025 per IRA provisions) may further reduce costs for some members [10].

Alternatives to Prolia That Humana May Cover More Easily

If PA for Prolia is denied, three other osteoporosis drug classes are covered at lower cost-sharing tiers on most Humana plans.

Oral Bisphosphonates

Alendronate 70 mg weekly and risedronate 35 mg weekly are generic Tier 1 or Tier 2 drugs on essentially all Humana Part D formularies, typically available for under $10 per month. These remain first-line per AACE 2020 guidelines [5] for patients without contraindications. The FLEX trial and the HORIZON Key Fracture Trial (N=7,765) support bisphosphonate use for fracture prevention [11].

Zoledronic Acid (Reclast)

Zoledronic acid 5 mg IV annually is administered in an infusion center and billed under the medical benefit, similar to Prolia. It is generally available at lower cost-sharing than Prolia because generic versions entered the market after 2019 [12]. This is a reasonable alternative for patients who cannot tolerate oral bisphosphonates.

Romosozumab (Evenity) and Teriparatide (Forteo)

Both romosozumab and teriparatide are reserved for patients at very high fracture risk per AACE/ACE guidelines [5]. Humana PA criteria for these anabolic agents are stricter than for Prolia, and prior bisphosphonate or Prolia failure is typically required. However, they represent viable escalation options in complex cases with multiple prior fractures.

Key Safety Considerations That Affect Coverage Decisions

Prolia's safety profile directly affects PA approval and the clinical documentation your physician submits.

Hypocalcemia Risk

Prolia carries a black box warning for hypocalcemia [13]. Humana PA reviewers look for documentation that baseline serum calcium was checked and corrected before initiation. The FDA label specifies that hypocalcemia must be treated before beginning Prolia therapy [13]. Including calcium and vitamin D supplementation plans in the PA packet addresses this requirement proactively.

Renal Function

Unlike oral bisphosphonates, Prolia does not require dose adjustment in chronic kidney disease and is one of the few osteoporosis agents safe in patients with eGFR <35 mL/min/1.73m² [14]. This is a strong clinical justification for Prolia over bisphosphonates in CKD patients and should be stated explicitly in the medical necessity letter.

Osteonecrosis of the Jaw and Atypical Femoral Fractures

Both osteonecrosis of the jaw (ONJ) and atypical femoral fractures are rare adverse events reported with Prolia [13]. Incidence of ONJ with Prolia is estimated at 0.04% per patient-year in osteoporosis patients versus higher rates in oncology doses [15]. These risks are low enough that they do not typically prevent PA approval in appropriate candidates.

The Rebound Effect After Prolia Discontinuation

Rapid bone loss and rebound vertebral fractures occur in a subset of patients who stop Prolia without transitioning to a bisphosphonate [16]. The Endocrine Society clinical practice guideline notes that sequential bisphosphonate therapy is recommended after Prolia discontinuation [17]. This clinical reality strengthens the case for maintaining Prolia coverage long-term once initiated, which your physician can argue during an appeal for continued authorization.

What Physicians Should Document to Maximize Approval

"Documentation is the single most common point of failure in specialty drug prior authorization," according to the American Society of Health-System Pharmacists' guidance on specialty biologics [18]. Physicians submitting Prolia PA to Humana should include:

• The specific T-score value and the date and facility of the DXA scan
• A written summary of bisphosphonate trial duration, dose, and reason for failure or contraindication
• Calculated FRAX probability (available free at sheffield.ac.uk/FRAX)
• Current serum calcium and eGFR lab values dated within 90 days
• Explicit statement of fracture risk category (high or very high) per AACE 2020 criteria [5]
• Any prior fragility fractures with imaging confirmation

Incomplete submissions are the leading cause of automatic denial before clinical review even begins.